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Abstract 
A recent meta-analysis of antidepressant trials is the largest conducted to date. Although it 
claims to prove antidepressant effectiveness beyond dispute, the main outcome is response 
rates, which are derived from continuous data in a process that can inflate differences 
between groups. The standardised mean difference of 0.3 is in line with other meta-
analyses that show small differences between antidepressants and placebo that are unlikely 
to be clinically significant. Other factors likely to exaggerate effects are discussed, and 
evidence on associations between antidepressant effects and severity, and outcomes of 
long-term treatment is considered. Clinicians need to have open discussions with patients 
about the limitations of antidepressant research, the lack of evidence that they correct a 
chemical imbalance or other brain abnormality, and the range of adverse effects and mental 
and physical alterations antidepressants can produce.  
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A recent meta-analysis of antidepressant trials (Cipriani et al., 2018) was greeted by media 
coverage declaring that ‘the drugs do work’ and that doubts about their usefulness should 
be ‘put to rest.’ Some of the authors called for wider prescribing, suggesting that 1 million 
more people in the UK should be prescribed antidepressants (Boseley, 2018).  
 
The latest meta-analysis, undertaken by Andrea Cipriani and colleagues, is the largest to 
have been undertaken, and included some unpublished as well as published studies. It 
employed a network analysis method, including data from comparative trials that did not 
include a placebo group. Included trials evaluated short-term treatment with 
antidepressants for an average of eight weeks. The principal efficacy outcome, ‘response’ 
rate, showed odds ratios of between 2.13 for amitriptyline and 1.37 for reboxetine, 
indicating that patients treated with antidepressants were approximately one and a half to 
two times more likely to show a response than patients treated with a placebo (Cipriani et 
al., 2018).  
‘Response’ is an artificial category, however. It is arbitrarily constructed out of scores on 
depression rating scales, such as the Hamilton Rating Scale for Depression (HRSD), which is 
the data that is actually collected from participants. The assumption that a 50% decrease in 
scores (the usual definition of response) represents a clinically meaningful improvement has 
not been validated. Moreover, categorising data can inflate small differences in raw scores, 
especially if the cut-off is close to the mean score, which it frequently is (Kirsch & Moncrieff, 
2007).  
The Standardised Mean Difference for the difference in rating scale scores in the Cipriani et 
al (2018) meta-analysis was 0.3, which is comparable with several other meta-analyses 
conducted over the last two decades. These show that SMDs of around 0.3 translate into 
differences in HRSD scores of around 2 points (Kirsch et al., 2002), which is unlikely to be 
clinically relevant. Research comparing HRSD scores with scores on the Clinical Global 
Impressions (CGI) scale  suggest that such a difference would not even be noticed, with a 
difference of at least 8 points being required to register as ‘mild improvement’ (Moncrieff & 
Kirsch, 2015).   
However, even these small differences are easily accounted for by the fact that 
antidepressants produce more or less subtle mental and physical alterations (e.g. nausea, 
dry mouth, dizziness, drowsiness and emotional blunting) irrespective of whether or not 
they treat depression. These alterations enable participants to guess whether they have 
been allocated to antidepressant or placebo better than would be expected by chance.  
Participants receiving the active drugs may therefore experience amplified placebo effects. 
This may explain why antidepressants that cause the most noticeable alterations, such as 
amitriptyline, appeared to be the most effective in the Cipriani et al (2018) meta-analysis.   
Another problem is that antidepressant trials often include people who are already on 
antidepressants, and who are withdrawn from them prior to the trial. Although there is 
usually a ‘placebo washout’ period during which participants are withdrawn from previous 
medication, we know that withdrawal effects can persist for longer than the one to two 
weeks that such periods usually last. Since trials do not try to identify antidepressant 
withdrawal effects, they may be misclassified as symptoms of depression in people who are 
subsequently randomised to placebo.  
 
The use of network meta-analysis is also likely to have inflated differences between 
antidepressants and placebo. People treated with antidepressants in placebo-controlled 
trials show lower response rates than participants in comparative trials that lack a placebo 
group, indicating how outcomes are influenced by expectations of receiving active therapy 
(Sinyor et al., 2010). Therefore network analysis includes data on antidepressants that is 
collected in more favourable circumstances than the data on placebo.   
 
The Cipriani meta-analysis only looked at data on short-term treatment, whereas in real life 
people increasingly take antidepressants for years. Few randomised, placebo-controlled 
trials have investigated long-term effects. In the large longitudinal STAR-D study, the 
proportion of people who adhered to recommended treatment, recovered and did not 
relapse was startlingly low (only 108 out of the 3110 people who satisfied inclusion criteria) 
(Pigott et al., 2010).  
 
Some evidence indicates that people with more severe depression show greater relative 
differences between antidepressants and placebo than those with less severe symptoms. 
However, other studies have not detected an association with severity (Gibbons et al., 2012, 
Walsh et al., 2002). In one meta-analysis that detected a severity effect, the difference 
between drug and placebo among those with severe depression was 4 points on the HRSD, 
which still falls well below the level that would indicate minimal improvement on the CGI 
(Kirsch et al., 2008).  
 
The recent meta-analysis does not resolve recent debates about the utility of 
antidepressants, but clinical guidelines continue to recommend them, and many people 
expect to be offered them. Much of the general public has also been persuaded that 
depression is caused by a chemical ‘imbalance’ that antidepressants correct, even though 
the evidence for this idea was never convincing. Indeed, despite speculation about a 
number of physiological processes, the mechanism through which antidepressants might 
affect symptoms of depression remains unknown. 
 Antidepressants are not placebos, however. They are active drugs that produce a range of 
physical and mental alterations. Some of the alterations they produce, such as the sedation 
induced by tricyclics, or the emotional blunting associated with SSRIs, may plausibly be 
useful for various psychological symptoms. However, the evidence reviewed above suggests 
the utility of these effects for the treatment of depression specifically is minimal. Moreover, 
some alterations are harmful or unpleasant, such as sexual dysfunction, which in some cases 
seems to persist after discontinuation of the drug (Farnsworth & Dinsmore, 2009) and 
agitation, suicidal and aggressive behaviour which can occur among younger users in 
particular (Sharma et al., 2016). Although serious adverse effects are probably rare, we have 
little data on the frequency or mechanisms of such effects, or how to treat them.  
 
Patients and clinicians need to consider all these factors if they are to make informed 
decisions about whether to use antidepressants or not. In particular, clinicians need to 
discuss the limitations of research on the efficacy and effectiveness of antidepressants, the 
lack of support for the idea that antidepressants correct a chemical imbalance or other brain 
abnormality and the range of adverse effects and mental and physical alterations that 
antidepressants can produce.  
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